Navigation Links
Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Date:12/2/2008

IRVINE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today announced the addition of veteran medical device executive and an experienced public company director, Raymond W. Cohen as a member of the Company's Board of Directors, increasing the number of board members to six.

Mr. Cohen, 49, has over 25 years of executive experience in the medical technology field and is currently the Chief Executive Officer and a member of the Board of Directors of Symphony Medical Inc., a venture-capital backed developer of novel biotherapeutic therapies to treat heart failure and other cardiac abnormalities.

For the decade prior to 2006, Cohen served as Chairman and CEO of publicly traded Cardiac Science, Inc. having served in that role during the period of rapid revenue growth and through the company's merger with Quinton Cardiology in late 2005. Today Cardiac Science is a leading manufacturer of automated public-access defibrillators and diagnostic cardiology systems, generating over $200 million in annual revenue. Cohen continues to serve on the board of Cardiac Science and also serves on the boards of BioLife Solutions, Inc., a publicly traded company, and BioGenex, Inc., and Syncroness, Inc.

Paul J. McCormick, the Company's Chairman of the Board commented, "Mr. Cohen has a solid track record of success in developing and commercializing innovative medical technology, particularly in the cardiovascular market. He brings the vision, insight and skills necessary to make a significant contribution to the Cardiogenesis Board of Directors and our shareholders. We are very pleased to have Mr. Cohen join our board and look forward to working with him."

About Cardiogenesis Corporation

Cardiogenesis specializes in provi
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cardiogenesis Reports Third Quarter 2008 Results
2. Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
3. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
4. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
5. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
6. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
7. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
8. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
9. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
10. Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
11. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... MADISON, N.J., Nov. 20 At a meeting of the ... today, a dividend of fifty cents($0.50) per share on the ... 2009 to stockholders of record at the close of business,on ... Wyeth is one of the world,s largest research-driven pharmaceutical and,health ...
... SIAL ),announced today the global release of MISSION(R) ... QUALITY and iScale Oligos(TM) siRNA are,expected to allow researchers ... with the highest purity and quality siRNA required for ... be well suited to target,validation and pre-clinical siRNA testing. ...
... 20 Nephros, Inc. (Amex: NEP ), a medical device company developing ... an update on its operations and strategy. , , ... , Appointed James Scibetta ... Ernest Elgin III President and CEO , Submitted ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/24/2014)... fungus could now be treated in three days, rather than ... , Cryptococcus a form of yeast - ... research. They are found in many parts of the ... affect people with weakened immune systems. This infection kills up ... has tested the effects of the most commonly used drug ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
(Date:4/24/2014)... of clear liquid can bend light, acting as a ... developed a new process to create inexpensive high quality ... , Because they,re so inexpensive, the lenses can ... to detect diseases in the field, scientific research in ... in classrooms. , "What I,m really excited about ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Amazon rainforest survey could improve carbon offset schemes 2Bake your own droplet lens 2Bake your own droplet lens 3
... While researching methods to increase the already well-recognized ... Illinois also found a way to prolong the vegetable,s ... study, the method is a natural and inexpensive way ... and won,t spoil so quickly on your refrigerator shelf. ...
... disease is the most common form of birth defect, ... the National Institutes of Health. Researchers from the University ... treat laboratory mice with one form of congenital heart ... caused by abnormally thick muscle. By suppressing a faulty ...
... vegetables are associated with higher Body Mass Index (BMI) ... to American University researchers in the journal Pediatric ... between the prices of fruit and vegetables and higher ... and assistant professor of public administration and policy at ...
Cached Biology News:Better broccoli, enhanced anti-cancer benefits with longer shelf life 2Better broccoli, enhanced anti-cancer benefits with longer shelf life 3Compound improves cardiac function in mice with genetic heart defect, MU study finds 2High cost of fruits, vegetables linked to higher body fat in young children 2
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... Probes intensely fluorescent and highly photostable ... use in a variety of applications ... strong signal. Unfortunately, protein- and other ... may cause them to bind to ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Description: Proteinase K is a highly active and ... applications purified from the fungus T. album. It ... of N-substituted hydrophobic aliphatic and aromatic amino acids ... protease. Proteinase K is useful in purifying high ...
Biology Products: